The HIF-2α antagonist PT2385 exhibited a significant therapeutic effect in the phase I clinical trials of other tumor types such as human renal clear cell carcinoma and did not cause side effects such as cardiotoxicity and hypertension (56). Here, EPAS1 is linked to neoplasm.